Skip to main navigation
Skip to search
Skip to main content
Fujita Health University Home
English
日本語
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial
AFIRE Investigators
Division of Cardiology
Research output
:
Contribution to journal
›
Article
›
peer-review
17
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Coronary Stenting
100%
Atrial Fibrillation
100%
Monotherapy
100%
Rivaroxaban
100%
Stenting
57%
Coronary Artery Disease
28%
Combination Therapy
28%
Antiplatelet
28%
Revascularization
14%
Myocardial Infarction
14%
Apoplexy
14%
Subgroup Analysis
14%
Blood Stasis
14%
Unstable Angina Pectoris
14%
Thrombosis
14%
Major Bleeding
14%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Monotherapy
100%
Rivaroxaban
100%
Combination Therapy
28%
Coronary Artery Disease
28%
Antiplatelet
28%
Bleeding
14%
Heart Infarction
14%
Thrombosis
14%
Blood Stasis
14%
Unstable Angina Pectoris
14%
Keyphrases
Therapy Cessation
14%
Clinical Time
14%